Long time follower but have never owned. The target market for this product seems to be huge and it is difficult not to be impressed at how the company has gotten a foothold in several markets across the world.
The company's financial position is improving with their first quarter of positive operating cashflows, however recall that the commentary in the previous (3rd quarter) noted that a large receipt of $330,000 that was expected in March didn't arrive until April.
Thus if that receipt arrived as expected in March the current (4th quarter) would have been cashflow negative and the 3rd quarter, even with the addition of the $330k receipt, would also have been negative. Adding the two quarters together still shows negative operating cashflows of -$449k for the last 6 months of FY10. That is the best 6 month performance since the company transitioned to focusing purely on Phoslock, however it is still not enough to stop the cash bleed.
At current rates the company will be out of cash in 6 months although in their announcement on June 21st the company stated that:
"The outlook for the next two quarters is very positive with the company expecting these two quarters to be cashflow positive"
They'll need to be if the company is to avoid coming back to market for a capital raising. Could today's action just be attributed to someone wanting out or a whiff of a capital raising in the air?
- Forums
- ASX - By Stock
- in the news
PET
phoslock environmental technologies limited
Add to My Watchlist
0.00%
!
2.5¢

Long time follower but have never owned. The target market for...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
2.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.60M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
PET (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online